Approval Of Astellas’ Myrbetriq Shows FDA’s Faith In Post-Marketing Studies
This article was originally published in The Pink Sheet Daily
Myrbetriq is approved for overactive bladder, but FDA requires trials looking at CV outcomes and malignant events, and lowers the starting dose from the sponsor’s proposal.
You may also be interested in...
CDER Director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.
Stephen Hahn will have over 100 stocks to divest upon becoming FDA commissioner.
US FDA will miss goal dates to reach speedier generic drug application approvals, but says decisions will be case by case.